Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.

Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V.

Ann Oncol. 2019 Mar 1;30(3):471-477. doi: 10.1093/annonc/mdy549.

2.

Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.

Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK.

Cancer. 2018 Sep 15;124(18):3693-3705. doi: 10.1002/cncr.31600. Epub 2018 Oct 5.

3.

Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation.

Frank SJ, Blanchard P, Lee JJ, Sturgis EM, Kies MS, Machtay M, Vikram B, Garden AS, Rosenthal DI, Gunn GB, Fuller CD, Hutcheson K, Lai S, Busse PM, Lee NY, Lin A, Foote RL.

Semin Radiat Oncol. 2018 Apr;28(2):108-113. doi: 10.1016/j.semradonc.2017.12.002.

4.

Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.

Gold KA, Kies MS, William WN Jr, Johnson FM, Lee JJ, Glisson BS.

Cancer. 2018 May 15;124(10):2169-2173. doi: 10.1002/cncr.31346. Epub 2018 Mar 26.

5.

Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.

Ferrarotto R, Cardnell R, Su S, Diao L, Eterovic AK, Prieto V, Morrisson WH, Wang J, Kies MS, Glisson BS, Byers LA, Bell D.

Head Neck. 2018 Aug;40(8):1676-1684. doi: 10.1002/hed.25146. Epub 2018 Mar 23.

6.

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas.

William WN Jr, Tsao AS, Feng L, Ginsberg LE, Lee JJ, Kies MS, Glisson BS, Kim ES.

Oncologist. 2018 May;23(5):526-e49. doi: 10.1634/theoncologist.2017-0661. Epub 2018 Jan 25.

7.

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00002. Epub 2017 Sep 8.

8.

Nasopharyngeal carcinoma presenting as an inconspicuous primary lesion with extensive cavernous sinus involvement and temporal lobe extension: a case report and review of literature.

Pollard C 3rd, Mesko SM, Ginsberg LE, Kies MS, Raza SM, Su SY, Tung S, Phan J.

Clin Case Rep. 2017 Sep 5;5(10):1682-1688. doi: 10.1002/ccr3.1166. eCollection 2017 Oct.

9.

Outcomes for olfactory neuroblastoma treated with induction chemotherapy.

Su SY, Bell D, Ferrarotto R, Phan J, Roberts D, Kupferman ME, Frank SJ, Fuller CD, Gunn GB, Kies MS, Glisson BS, Hanna EY.

Head Neck. 2017 Aug;39(8):1671-1679. doi: 10.1002/hed.24822. Epub 2017 May 31.

PMID:
28561956
10.

Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx.

Shiao JC, Mohamed ASR, Messer JA, Hutcheson KA, Johnson JM, Enderling H, Kamal M, Warren BW, Pham B, Morrison WH, Zafereo ME, Hessel AC, Lai SY, Kies MS, Ferrarotto R, Garden AS, Schomer DF, Gunn GB, Phan J, Frank SJ, Beadle BM, Weber RS, Lewin JS, Rosenthal DI, Fuller CD.

Head Neck. 2017 Aug;39(8):1609-1620. doi: 10.1002/hed.24804. Epub 2017 May 2.

11.

Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review.

Hutcheson KA, Yuk M, Hubbard R, Gunn GB, Fuller CD, Lai SY, Lin H, Garden AS, Rosenthal DI, Hanna EY, Kies MS, Lewin JS.

Head Neck. 2017 Aug;39(8):1516-1523. doi: 10.1002/hed.24789. Epub 2017 Apr 28. Review.

12.

Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base.

Garden AS, Fuller CD, Rosenthal DI, William WN Jr, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM.

Cancer. 2016 Nov 15;122(21):3411-3412. doi: 10.1002/cncr.30193. Epub 2016 Jul 15. No abstract available.

13.

Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer.

McKeever MR, Sio TT, Gunn GB, Holliday EB, Blanchard P, Kies MS, Weber RS, Frank SJ.

Chin Clin Oncol. 2016 Aug;5(4):54. doi: 10.21037/cco.2016.07.03. Epub 2016 Aug 2. Review.

14.

Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy.

Goepfert RP, Lewin JS, Barrow MP, Gunn GB, Fuller CD, Beadle BM, Garden AS, Rosenthal DI, Kies MS, Papadimitrakopoulou V, Lai SY, Gross ND, Schwartz DL, Hutcheson KA.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):700-708. doi: 10.1016/j.ijrobp.2016.06.010. Epub 2016 Jun 15.

15.

Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches.

Fuller CD, Mohamed AS, Garden AS, Gunn GB, Mulcahy CF, Zafereo M, Phan J, Lai SY, Lewin JS, Hutcheson KA, Frank SJ, Beadle BM, Morrison WH, El-Naggar AK, Kocak-Uzel E, Ginsberg LE, Kies MS, Weber RS, Rosenthal DI.

Head Neck. 2016 Dec;38(12):1739-1751. doi: 10.1002/hed.24532. Epub 2016 Jul 28. Erratum in: Head Neck. 2017 Jul;39(7):1484-1496.

16.

Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.

Goepfert RP, Lewin JS, Barrow MP, Fuller CD, Lai SY, Song J, Hobbs BP, Gunn GB, Beadle BM, Rosenthal DI, Garden AS, Kies MS, Papadimitrakopoulou VA, Schwartz DL, Hutcheson KA.

Laryngoscope. 2017 Apr;127(4):842-848. doi: 10.1002/lary.26153. Epub 2016 Jul 21.

17.

Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis.

Blanchard P, Garden AS, Gunn GB, Rosenthal DI, Morrison WH, Hernandez M, Crutison J, Lee JJ, Ye R, Fuller CD, Mohamed AS, Hutcheson KA, Holliday EB, Thaker NG, Sturgis EM, Kies MS, Zhu XR, Mohan R, Frank SJ.

Radiother Oncol. 2016 Jul;120(1):48-55. doi: 10.1016/j.radonc.2016.05.022. Epub 2016 Jun 21.

18.

Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma.

Gunn GB, Blanchard P, Garden AS, Zhu XR, Fuller CD, Mohamed AS, Morrison WH, Phan J, Beadle BM, Skinner HD, Sturgis EM, Kies MS, Hutcheson KA, Rosenthal DI, Mohan R, Gillin MT, Frank SJ.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):360-367. doi: 10.1016/j.ijrobp.2016.02.021. Epub 2016 Feb 12.

19.

Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma.

Esmaeli B, Yin VT, Hanna EY, Kies MS, William WN Jr, Bell D, Frank SJ.

Head Neck. 2016 Aug;38(8):1258-62. doi: 10.1002/hed.24433. Epub 2016 Mar 29.

PMID:
27027275
20.

Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer.

Garden AS, Fuller CD, Rosenthal DI, William WN Jr, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM.

Cancer. 2016 Jun 1;122(11):1702-7. doi: 10.1002/cncr.29965. Epub 2016 Mar 28.

21.

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.

Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA.

Oncotarget. 2016 Apr 26;7(17):23227-38. doi: 10.18632/oncotarget.7594.

22.

Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma.

Holliday E, Bhattasali O, Kies MS, Hanna E, Garden AS, Rosenthal DI, Morrison WH, Gunn GB, Phan J, Zhu XR, Zhang X, Frank SJ.

Int J Part Ther. 2016 Mar;2(4):533-543. doi: 10.14338/IJPT-15-00032.1. Epub 2016 Mar 24.

23.

Depression and Oropharynx Cancer Outcome.

Shinn EH, Valentine A, Jethanandani A, Basen-Engquist K, Fellman B, Urbauer D, Atkinson E, Yusuf SW, Lenihan D, Woods ML, Kies MS, Sood AK, Carmack C, Morrison WH, Gillenwater A, Sturgis EM, Garden AS.

Psychosom Med. 2016 Jan;78(1):38-48. doi: 10.1097/PSY.0000000000000256.

24.

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE.

Ann Oncol. 2016 Feb;27(2):318-23. doi: 10.1093/annonc/mdv537. Epub 2015 Nov 23.

25.

Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer.

Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, Johnson FM, Gunn GB, Fuller CD, Phan J, Gold KA, Frank SJ, Skinner H, Rosenthal DI, Garden AS.

Head Neck. 2016 Apr;38 Suppl 1:E1554-61. doi: 10.1002/hed.24278. Epub 2015 Nov 23.

PMID:
26595157
26.

Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature.

Bhattasali O, Holliday E, Kies MS, Hanna EY, Garden AS, Rosenthal DI, Morrison WH, Gunn GB, Fuller CD, Zhu XR, Frank SJ.

Head Neck. 2016 Apr;38 Suppl 1:E1472-80. doi: 10.1002/hed.24262. Epub 2015 Nov 11. Review.

PMID:
26561041
27.

A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa.

Holliday EB, Esmaeli B, Pinckard J, Garden AS, Rosenthal DI, Morrison WH, Kies MS, Gunn GB, Fuller CD, Phan J, Beadle BM, Zhu XR, Zhang X, Frank SJ.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):344-352. doi: 10.1016/j.ijrobp.2015.08.008. Epub 2015 Aug 7.

PMID:
26454680
28.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

29.

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR Jr, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V.

Ann Oncol. 2015 Jul;26(7):1476-80. doi: 10.1093/annonc/mdv194. Epub 2015 May 29.

30.

Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients.

Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN.

Cancer Res. 2015 Apr 1;75(7):1205-15. doi: 10.1158/0008-5472.CAN-14-2729. Epub 2015 Feb 17.

31.

Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy.

Bishop AJ, Garden AS, Gunn GB, Rosenthal DI, Beadle BM, Fuller CD, Levy LB, Gillenwater AM, Kies MS, Esmaeli B, Frank SJ, Phan J, Morrison WH.

Head Neck. 2016 Apr;38 Suppl 1:E452-8. doi: 10.1002/hed.24017. Epub 2015 Jul 14.

PMID:
25645649
32.

Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.

Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, Hsu TK, Pickering CR, Ward A, Patel A, Yordy JS, Skinner HD, Giri U, Sano D, Story MD, Beadle BM, El-Naggar AK, Kies MS, William WN, Caulin C, Frederick M, Kimmel M, Myers JN, Lichtarge O.

Cancer Res. 2015 Apr 1;75(7):1527-36. doi: 10.1158/0008-5472.CAN-14-2735. Epub 2015 Jan 29.

33.

Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey.

Rosenthal DI, Mohamed AS, Weber RS, Garden AS, Sevak PR, Kies MS, Morrison WH, Lewin JS, El-Naggar AK, Ginsberg LE, Kocak-Uzel E, Ang KK, Fuller CD.

Cancer. 2015 May 15;121(10):1608-19. doi: 10.1002/cncr.29241. Epub 2015 Jan 13.

34.

Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.

Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman SM, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK.

Clin Cancer Res. 2014 Dec 15;20(24):6570-81. doi: 10.1158/1078-0432.CCR-14-1746. Epub 2014 Oct 14.

35.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87.

36.

Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.

Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K.

J Clin Oncol. 2014 Aug 10;32(23):2486-95. doi: 10.1200/JCO.2013.53.9163. Epub 2014 Jul 7.

37.

Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer.

Garden AS, Gunn GB, Hessel A, Beadle BM, Ahmed S, El-Naggar AK, Fuller CD, Byers LA, Phan J, Frank SJ, Morrison WH, Kies MS, Rosenthal DI, Sturgis EM.

Cancer. 2014 Oct 1;120(19):3082-8. doi: 10.1002/cncr.28831. Epub 2014 Jun 4.

38.

Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice.

Frank SJ, Cox JD, Gillin M, Mohan R, Garden AS, Rosenthal DI, Gunn GB, Weber RS, Kies MS, Lewin JS, Munsell MF, Palmer MB, Sahoo N, Zhang X, Liu W, Zhu XR.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):846-53. doi: 10.1016/j.ijrobp.2014.04.019. Epub 2014 May 24.

39.

Phase II study of gefitinib in patients with advanced salivary gland cancers.

Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR Jr.

Head Neck. 2015 May;37(5):644-9. doi: 10.1002/hed.23647. Epub 2015 Mar 30.

40.

Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.

Blumenschein GR Jr, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J Jr, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM.

Clin Cancer Res. 2013 Dec 15;19(24):6967-75. doi: 10.1158/1078-0432.CCR-12-1818. Epub 2013 Oct 28.

41.

Prognostic factors associated with decreased survival in patients with acinic cell carcinoma.

Neskey DM, Klein JD, Hicks S, Garden AS, Bell DM, El-Naggar AK, Kies MS, Weber RS, Kupferman ME.

JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1195-202. doi: 10.1001/jamaoto.2013.4728.

42.

Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.

Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Aug;11(8):917-23. Erratum in: J Natl Compr Canc Netw. 2013 Dec 1;11(12):1458.

PMID:
23946171
43.

MicroRNA profiling of salivary adenoid cystic carcinoma: association of miR-17-92 upregulation with poor outcome.

Mitani Y, Roberts DB, Fatani H, Weber RS, Kies MS, Lippman SM, El-Naggar AK.

PLoS One. 2013 Jun 25;8(6):e66778. doi: 10.1371/journal.pone.0066778. Print 2013.

44.

Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck.

Hutcheson KA, Lewin JS, Holsinger FC, Steinhaus G, Lisec A, Barringer DA, Lin HY, Villalobos S, Garden AS, Papadimitrakopoulou V, Kies MS.

Head Neck. 2014 Apr;36(4):474-80. doi: 10.1002/hed.23330. Epub 2013 Jun 18.

45.

The role of trastuzumab in the management of salivary ductal carcinomas.

Perissinotti AJ, Lee Pierce M, Pace MB, El-Naggar A, Kies MS, Kupferman M.

Anticancer Res. 2013 Jun;33(6):2587-91.

PMID:
23749912
46.

Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance.

Zhang L, Mitani Y, Caulin C, Rao PH, Kies MS, Saintigny P, Zhang N, Weber RS, Lippman SM, El-Naggar AK.

Am J Pathol. 2013 Jun;182(6):2048-57. doi: 10.1016/j.ajpath.2013.02.020. Epub 2013 Apr 10.

47.

Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century.

Garden AS, Kies MS, Morrison WH, Weber RS, Frank SJ, Glisson BS, Gunn GB, Beadle BM, Ang KK, Rosenthal DI, Sturgis EM.

Radiat Oncol. 2013 Jan 29;8:21. doi: 10.1186/1748-717X-8-21.

48.

Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.

El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli B.

Arch Ophthalmol. 2012 Dec;130(12):1608-11. doi: 10.1001/archophthalmol.2012.2515. No abstract available.

PMID:
23229707
49.

Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.

Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY.

J Clin Oncol. 2013 Feb 20;31(6):744-51. doi: 10.1200/JCO.2012.43.8820. Epub 2012 Nov 5.

50.

Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival.

Sandulache VC, Ow TJ, Daram SP, Hamilton J, Skinner H, Bell D, Rosenthal DI, Beadle BM, Ang KK, Kies MS, Johnson FM, El-Naggar AK, Myers JN.

Head Neck. 2013 Oct;35(10):1454-60. doi: 10.1002/hed.23173. Epub 2012 Sep 28.

PMID:
23018868

Supplemental Content

Support Center